Clinical trials appendix
As of 12 November 2024
Filter by
Asset | Trial | Population | Patients | Design | Endpoints | Status | Development stage | Indication |
---|---|---|---|---|---|---|---|---|
Asset
Wainua
(eplontersen, ligand-conjugated antisense)
|
Trial
CVRM
Phase III
CARDIO-TTRansform
NCT04136171
Partnered (Ionis Pharmaceuticals, Inc.)
|
Population
Hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
|
Patients
1438
|
Design
|
Endpoints
|
Status
|
Development stage
Approved medicines
|
Indication
Amyloidosis
|
Asset
Wainua
(eplontersen, ligand-conjugated antisense)
|
Trial
CVRM
Phase III
NEURO-TTRansform
NCT04136184
Partnered (Ionis Pharmaceuticals, Inc.)
|
Population
Hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
|
Patients
168
|
Design
|
Endpoints
|
Status
|
Development stage
Approved medicines
|
Indication
Amyloidosis
|
Asset
Wainua
(eplontersen, ligand-conjugated antisense)
|
Trial
CVRM
Phase III
EPIC-ATTR
NCT06194825
|
Population
ATTR-CM
|
Patients
64
|
Design
|
Endpoints
|
Status
|
Development stage
Approved medicines
|
Indication
Amyloidosis
|
Asset
AZD0233
(oral CX3CR1)
|
Trial
CVRM
Phase I
NCT06381466
|
Population
Healthy volunteers
|
Patients
96
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Healthy volunteer
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase II
PURSUIT
NCT06173570
|
Population
Dyslipidaemia
|
Patients
428
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Dyslipidaemia
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase II
NCT06692764
|
Population
Participants with ASCVD or risk equivalents and LDL-C ≥70 mg/dL on stable medication
|
Patients
172
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Dyslipidaemia
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase I
NCT05384262
|
Population
Healthy volunteers
|
Patients
183
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Healthy volunteer
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase I
NCT05787002
|
Population
Healthy volunteers
|
Patients
16
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Healthy volunteer
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase I
NCT05817461
|
Population
Healthy volunteers
|
Patients
8
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Healthy volunteer
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase I
NCT06576765
|
Population
Hepatic impairment and matched healthy controls
|
Patients
32
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Dyslipidaemia
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase I
NCT06592482
|
Population
Renal impairment and matched healthy controls
|
Patients
42
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Dyslipidaemia
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase I
NCT06671405
|
Population
Healthy volunteers
|
Patients
78
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Dyslipidaemia
|
Asset
AZD0780
(PCSK9 inhibitor)
|
Trial
CVRM
Phase I
NCT06742853
|
Population
Healthy volunteers with elevated LDL-C
|
Patients
120
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Dyslipidaemia
|
Asset
AZD1705
(Angptl3 inhibitor)
|
Trial
CVRM
Phase I
NCT06238466
|
Population
Dyslipidaemia
|
Patients
112
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Dyslipidaemia
|
Asset
AZD2373
(APOL1)
|
Trial
CVRM
Phase I
NCT04269031
|
Population
Healthy volunteers
|
Patients
30
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Healthy volunteer
|
Asset
AZD2373
(APOL1)
|
Trial
CVRM
Phase I
NCT05351047
|
Population
Healthy volunteers
|
Patients
24
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Healthy volunteer
|
Asset
AZD2389
(anti-fibrotic mechanism)
|
Trial
CVRM
Phase II
BORANA
NCT06750276
|
Population
Participants with liver fibrosis and compensated cirrhosis
|
Patients
36
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Liver disease
|
Asset
AZD2389
(anti-fibrotic mechanism)
|
Trial
CVRM
Phase I
NCT06138795
|
Population
Healthy volunteers
|
Patients
104
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Healthy volunteer
|
Asset
AZD2693
(PNPLA3 ASO)
|
Trial
CVRM
Phase IIb
FORTUNA
NCT05809934
|
Population
NASH with fibrosis
|
Patients
180
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Liver disease
|
Asset
AZD2693
(PNPLA3 ASO)
|
Trial
CVRM
Phase I
NCT04483947
|
Population
NASH/NAFLD F0-F3
|
Patients
74
|
Design
|
Endpoints
|
Status
|
Development stage
Early development
|
Indication
Liver disease
|